MRNS
vs
S&P 500
MRNS
S&P 500
Over the past 12 months, MRNS has significantly outperformed S&P 500, delivering a return of +139% compared to the S&P 500's +14% growth.
Stocks Performance
MRNS vs S&P 500
Performance Gap
MRNS vs S&P 500
Performance By Year
MRNS vs S&P 500
Compare the stock's returns with its benchmark index and competitors. Gain insights into its relative performance over time.
Marinus Pharmaceuticals Inc
Glance View
Marinus Pharmaceuticals, Inc. is a biopharmaceutical company, which engages in the identification and development of neuropsychiatric therapeutics. The company is headquartered in Radnor, Pennsylvania and currently employs 113 full-time employees. The company went IPO on 2014-07-31. The firm is focused on the development and commercialization of products for patients suffering from rare genetic epilepsies and other seizure disorders. The Company’s lead product candidate is ZTALMY (ganaxolone) oral suspension for the treatment of seizures associated with cyclin-dependent kinase-like 5 (CDKL5) deficiency disorder (CDD), which is developed for the treatment of seizures associated with cyclin-dependent kinase-like 5 (CDKL5) deficiency disorder (CDD). Ganaxolone is a methylated analog of the endogenous neurosteroid, allopregnanolone. Ganaxolone acts at both synaptic and extrasynaptic gamma-aminobutyric acid type A (GABAA) receptors, a target known for its anti-seizure, antidepressant, and anxiolytic potential.